ProSpec-Tany TechnoGene Ltd. (prospecbio), an internationally recognized manufacturer of recombinant proteins, today highlighted the groundbreaking potential of Ciliary Neurotrophic Factor (CNTF) in advancing the fight against devastating neurological diseases. With over two decades of expertise in protein production and more than 6,000 products in its portfolio, ProSpecBio is now drawing attention to CNTF’s role as a beacon of hope for patients suffering from neurodegenerative disorders.
CNTF: A Natural Protector of Nerve Cells
Ciliary Neurotrophic Factor, commonly known as CNTF, is a naturally occurring protein predominantly active in the nervous system. It is best known for its ability to:
-
Support the survival of neurons and oligodendrocytes.
-
Promote neurotransmitter synthesis and neurite outgrowth.
-
Prevent degeneration of motor neurons following axonal injury.
Unlike many growth factors that act broadly across tissues, CNTF’s activity is highly specialized, making it particularly significant in research on neuroprotection and regeneration. Mutations in the CNTF gene have been linked to deficiencies, but even more importantly, recombinant CNTF is now enabling scientists to study its therapeutic potential in controlled laboratory environments.
“Our mission has always been to provide scientists with the highest quality proteins at accessible prices. By making CNTF available in multiple formats, we are enabling both small academic labs and large pharmaceutical companies to explore its therapeutic potential.”, said a ProSpecBio spokesperson.
Recent Scientific Developments
In the last decade, CNTF has gained momentum in neuroscience research. Studies published in Nature and Science have demonstrated its role in preventing motor neuron degeneration in animal models, suggesting clinical relevance for conditions such as:
-
Amyotrophic Lateral Sclerosis (ALS): CNTF has been shown to delay the death of motor neurons, the hallmark of ALS.
-
Multiple Sclerosis (MS): Its ability to reduce tissue destruction during inflammatory episodes highlights potential benefits in immune-mediated demyelinating diseases.
-
Retinal Degeneration & Glaucoma: CNTF eye drops have shown neuroprotective effects in vision preservation, opening new avenues in ophthalmology.
-
Parkinson’s Disease: Preclinical research suggests CNTF’s regenerative pathways could complement dopamine-based therapies.
While much of this work is still in preclinical or early clinical stages, the consistent finding across multiple studies is that CNTF is not just a survival factor—it is also a regenerative signal for damaged nerve tissue.
ProSpecBio’s Contribution to CNTF Supply
For researchers to unlock CNTF’s therapeutic potential, reliable access to high-purity recombinant proteins is essential. ProSpecBio has responded to this need by making CNTF Human Recombinant (Cat# CYT-272) widely available to scientists worldwide.
-
Source: Produced in E. coli.
-
Purity: Greater than 98% as verified by SDS-PAGE and RP-HPLC.
-
Activity: Demonstrates potent biological activity with an ED50 of less than 2 ng/ml.
-
Formats Available: 5µg, 20µg, and 1mg vials, priced competitively for both academic and industrial research labs.
By leveraging proprietary purification technologies, ProSpecBio ensures that its CNTF is not only biologically active but also stable and reproducible across batches—qualities that are crucial for translational research.
Why This Matters Now
The global burden of neurodegenerative diseases is escalating as populations age. According to the World Health Organization, neurological disorders are now the leading cause of disability worldwide, affecting hundreds of millions of people. Treatments remain largely symptomatic, with no cure available for conditions like ALS, MS, or Alzheimer’s disease.
CNTF offers a scientific pathway toward therapies that do more than just slow symptoms—they hold the potential to preserve and restore neural function. By supplying CNTF to research institutions in North America, Europe, Asia, and beyond, ProSpecBio is directly contributing to the acceleration of scientific discovery and therapeutic innovation.
According to their spokesperson, “The excitement around CNTF is not just theoretical. We are already seeing promising data from neuroregeneration studies, and we believe our contribution will accelerate the journey from bench to bedside.
Challenges and Future Directions
Despite its promise, CNTF research faces several hurdles:
-
Delivery Barriers: CNTF does not easily cross the blood-brain barrier, complicating systemic administration.
-
Dosing & Safety: Finding the right therapeutic window is essential to avoid off-target effects.
-
Long-Term Studies: More clinical trials are needed to determine CNTF’s sustained efficacy in patients.
ProSpecBio emphasizes that while CNTF is not yet a therapeutic drug, its recombinant form is an indispensable tool for laboratories working to overcome these challenges.
About ProSpecBio
Founded over 20 years ago, ProSpec-Tany TechnoGene Ltd. has built a reputation as a trusted supplier of recombinant proteins, antibodies, and antigens for the global scientific community. With headquarters in Rehovot, Israel, and a distribution hub in East Brunswick, NJ, ProSpecBio serves universities, biotech firms, pharmaceutical companies, hospitals, and government research institutions across six continents.
Their catalog includes:
-
Cytokines
-
Growth Factors
-
Chemokines
-
CD Antigens
-
Neurotrophins (including CNTF, BDNF, NGF, and others)
-
Monoclonal & Polyclonal Antibodies
-
Custom Services such as DNA cloning, protein expression, fermentation, and antibody production
With a focus on quality, reliability, and customer service, ProSpecBio has become a partner of choice for life sciences research worldwide.
Media Contact
Company Name: ProSpec-Tany TechnoGene Ltd.
Contact Person:
Email: Send Email
Phone: +972-8-9471175
Address:PO Box 4157
City: Ness-Ziona
Country: Israel
Website: https://www.prospecbio.com/